Cardio Diagnostics Holdings, Inc. is set to showcase its innovative cardiovascular solutions at four key national benefits conferences this June, addressing the critical issue of cardiovascular disease (CVD), a leading cost driver for health plans.
The company will present its advanced blood tests, Epi+Gen CHD™ and PrecisionCHD™, which utilize a combination of epigenetics, genetics, and artificial intelligence to identify individuals at risk for severe cardiac events. These tests aim to enhance patient outcomes by detecting risk factors that traditional metrics like cholesterol and blood pressure might overlook. By leveraging these technologies, employers and brokers can implement more effective health strategies that not only reduce costs but also enhance workforce health.
Cardio Diagnostics will participate in several conferences, including the Greater Philadelphia Business Coalition on Health Annual Conference and the Midwest Employee Benefit Funds Coalition Annual Meeting. These events will facilitate discussions with industry stakeholders on the urgent need to mitigate the financial impact of CVD, which is preventable in a significant percentage of cases.
Dr. Meesha Dogan, CEO and Co-Founder, emphasized the dual benefits of their approach: reducing healthcare spending while promoting healthier lifestyles. The integration of their tests and the HeartRisk™ platform provides a tailored strategy for employers and unions to manage cardiovascular risks effectively, ultimately leading to a more productive workforce.
This proactive stance on cardiovascular health highlights the potential for innovation in healthcare to not only save costs but also improve overall employee well-being. As CVD remains a pressing concern, Cardio Diagnostics' solutions may represent a critical step forward in preventive healthcare.